Trifarotene

Overview

Trifarotene is a selective retinoic acid receptor (RAR) gamma agonist that is used topically to treat acne vulgaris. It helps by promoting cell turnover, thereby reducing acne severity and maintaining skin health.

API suppliers (1)

Suppliers of Trifarotene backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• HAS Healthcare Advanced Synthesis SASwitzerland1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Trifarotene expires 29 May 2033. Generic API sourcing typically opens up once these lapse.

Therapeutic areas